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Background: Limited utility data on patients suffering from overactive bladder (OAB) are available in the literature.
The objectives of this study were to estimate utility values in patients with OAB using the generic EQ-5D questionnaire
and the OAB-5D disease specific questionnaire, to investigate the relationship between utilities and symptoms, and to
evaluate the sensitivity of the two instruments to changes in symptom severity.
Methods: Analyses were based on pooled data from three large multicenter randomized 12-week placebo-controlled
trials (SCORPIO, ARIES, CAPRICORN). Patients completed a micturition diary, EQ-5D and OAB-q (a quality of life
questionnaire from which OAB-5D is derived) at baseline and at weeks 4, 8 and 12. Time trade-off tariffs elicited
from UK population were applied to obtain utilities from both instruments. Repeated measures regressions were
used to estimate EQ-5D and OAB-5D utilities by micturition frequency and incontinence severity level. As a test of
sensitivity of the instruments, utility changes from baseline to week 12 were estimated by symptomatic response
(improvement, stable or worsening).
Results: The sample included 4427 patients. Mean utilities (± standard deviation) across all visits were 0.82 (±0.21)
for EQ-5D and 0.86 (±0.09) for OAB-5D. Correlation between EQ-5D and OAB-5D was 0.34 (p < 0.0001). Both OAB-5D
and EQ-5D utilities increased as OAB symptoms improved. Utility values were similar for severe levels of symptoms, but
higher with OAB-5D than with EQ-5D for mild cases. Micturitions and incontinence had similar impact on EQ-5D
utilities, but micturitions had greater impact on OAB-5D utilities than incontinence. Changes from baseline in OAB-5D
utilities differed significantly according to symptomatic response. Changes in EQ-5D utilities were not significantly
associated with changes in micturition frequency and weakly associated with changes in incontinence severity
among patients with mild symptoms at baseline.
Conclusions: This study showed that both EQ-5D and OAB-5D can detect changes in severity of OAB, especially in
severe cases. However, OAB-5D is more sensitive than EQ-5D in measuring differences between treatments in
milder cases. Both OAB-5D and EQ-5D–although leading to different results–may be useful to derive utilities from
clinical trial data and perform cost-effectiveness analyses.
Trial registration: Clinical Trials NCT00689104, NCT00662909, NCT00912964.
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Overactive bladder (OAB) is a chronic condition defined
by the International Continence Society as urinary
urgency, with or without urgency incontinence, usually
with increased daytime frequency and nocturia [1].
Urgency is a sudden, compelling and difficult to defer
desire to pass urine. Symptoms can have significant im-
pact on a person’s health related quality of life (HRQoL),
interfering with daily routines, causing embarrassment
as well as lowered self-esteem. OAB is also associated
with an increased risk and prevalence of co morbidities,
including falls and fractures, urinary tract and skin in-
fections, and depression [2].
Previous reports from the European Prospective Investi-
gation into Cancer and Nutrition (EPIC) study estimated
the overall prevalence of OAB in Europe and Canada to
be 12.8% among women and 10.8% among men [3].
Estimates of health utilities associated with different
states of OAB are required for economic evaluations of
OAB treatments. Utilities represent individual’s prefer-
ences for specific health states. They are measured on a
scale where 0 represents death and 1 perfect health.
According to the methodological guidelines of the UK
National Institute for Health and Clinical Excellence
(NICE) [4] and the US Panel on Cost-Effectiveness in
Health and Medicine [5], quality adjusted life years
(QALYs) should be obtained by assigning values elicited
from the general public, to health states described by
persons with OAB, by means of a generic classification
of health states. NICE specifically advises the utilisation
of EQ-5D, a widely used generic HRQoL instrument.
Sets of utilities were generated for EQ-5D health states
in many countries using choice-based methods, such as
time trade-off (TTO) or standard gamble.
Only few data on utilities in OAB are available. EQ-5D
TTO utilities were obtained in a Swedish willingness to
pay survey among patients with urge incontinence [6,7].
This survey showed a correlation between EQ-5D utility
and urinary symptoms, measured as the sum of the num-
bers of micturitions and leakages over one day. However,
Yang et al. considered OAB as a condition for which
the generic dimensions of EQ-5D might be irrelevant or
insensitive for capturing small though important clinical
changes [8]. EQ-5D has a number of potential limita-
tions, such as the lack of sensitivity in specific disease
contexts [9-11].
To overcome these limitations, Yang et al. developed a
5-dimensional preference-based disease-specific measure,
named OAB-5D [see Additional file 1] and derived from
the Overactive Bladder Questionnaire (OAB-q) [8,12].
The OAB-q is a validated and widely used questionnaire
to assess symptom bother as well as HRQoL in OAB
patients [13-15]. Even though OAB-q was not originally
designed to measure utilities, Yang et al. built a model forderiving utilities from the 5 items forming the OAB-5D
system, based on a survey in the UK general population,
using the TTO method.
The objectives of this study were to estimate utility
values in patients with OAB using the generic EQ-5D
questionnaire and the OAB-5D disease specific question-
naire, to investigate the relationship between utilities and
symptoms, and to evaluate the sensitivity to the changes
in OAB symptoms of both preference-based instruments
based on data from three pooled clinical trials.
Methods
Patients and study design
This post-hoc analysis was based on pooled data from
three 12-week, randomized, double-blind, parallel group,
placebo controlled, multi-centre studies (SCORPIO [16],
ARIES [17] and CAPRICORN [18]) assessing the efficacy
against placebo of mirabegron, a first in class beta 3
adrenoreceptor agonist, in the treatment of patients with
symptoms of OAB. The three clinical trials had similar
inclusion and exclusion criteria. Four thousand six hundred
and twenty-two (4622) patients were randomized in
the three trials conducted across Australia, Europe,
United States of America and Canada. Male and female
patients ≥18 years of age were screened for enrollment
into the studies if they had OAB symptoms for at least
3 months. Patients were excluded if they had clinically
relevant stress incontinence or mixed stress/urgency
incontinence with stress as the predominant factor; an
indwelling catheter; evidence of a symptomatic urinary
tract infection, chronic inflammation, bladder stones,
previous pelvic radiation therapy, previous or current
malignant disease of the pelvic organs; or severe hyper-
tension. At baseline, patients must have experienced an
average of ≥8 micturitions/24 hours and ≥3 urgency epi-
sodes with/without incontinence over a 3-day period.
Patients underwent a 2-week placebo run-in period
followed at randomization by a 12-week phase where
1384 patients were administered placebo, 433 patients
mirabegron 25 mg, 1379 patients mirabegron 50 mg, 931
patients mirabegron 100 mg, and 495 the anti-muscarinic
tolterodine. A 3-day micturition diary, a generic HRQoL
questionnaire (EQ-5D) and a disease-specific HRQoL
questionnaire (OAB-q) were completed at baseline and
weeks 4, 8 and 12. These analyses were based on pooled
full analysis sets, which consisted of all randomized
patients taking at least one treatment medication dose.
Clinical measures and severity of symptoms
Patients completed a micturition diary over the 3 days
preceding each study visit. From the diary, the following
endpoints were derived: mean number of micturitions
per 24 hours, mean number of urgency episodes (grade
3 and 4) per 24 hours, mean number of incontinence
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micturition. For micturitions frequency and incontin-
ence episodes, 5 severity levels were defined roughly
based on the distribution (quintiles) of event observed
in the pooled trials, using all visits combined. For the
severity incontinence, class 1 (less severe) was composed
of continent patients (no incontinence episode reported
in the 3-day micturition diary).Preference based instruments
The EQ-5D instrument consists of 5 questions, relating
to mobility, self-care, usual activities, pain/discomfort
and anxiety/depression, with 3 possible answers for each
item, corresponding to “no problem”, “moderate problems”
or “extreme problems”. It can be used to calculate a utility
index score on a scale on which 0 represents a health
state equivalent to death and 1 represents full health.
The UK TTO tariff was used to derive EQ-5D utilities
in this study [19].
The OAB-q is a 33-item questionnaire consisting of an
8-item Symptom Bother scale and a 25-item HRQoL scale
that has four subscales: coping, concern, sleep, and social
interaction [13]. Responses are based on a six-point Likert
scale. The OAB-q has demonstrated good internal
consistency, reliability, test–retest reliability, concurrent
validity, discriminate validity, and responsiveness to
treatment-related change [13-15].
To value OAB health states, five items were chosen
from the OAB-q to construct a new health state classifi-
cation system (OAB-5D) namely: urge to urinate, urine
loss, sleep impact, coping strategy, and concern with OAB,
where each dimension had five levels of severity with level
1 denoting no problem and level 5 indicating an extreme
problem [8]. A total of 3125 health states can be defined by
the OAB-5D classification system (compared to 243 with
EQ-5D), and all OAB-q data which contain these five
items can be mapped to a specific OAB-5D health state.Statistical analysis
Utility scores derived from EQ-5D and OAB-5D were
first described as means and standard deviations and then
estimated by symptom severity. The Spearman correlation
coefficient between EQ-5D and OAB-5D utilities was
estimated.
For each type of symptom–micturition frequency and
incontinence episodes–a linear regression model was used
to estimate EQ-5D and OAB-5D utilities by symptom
level, adjusting for gender, age and study as fixed effects,
and geographical region as random effect. The correlation
between utility values for one individual at different
assessment visits was taken into account by means of
a random patient effect. Using a similar method, dif-
ferences between OAB-5D and EQ-5D utilities wereestimated by symptom level, and tested for the null hy-
pothesis of equal mean OAB-5D and EQ-5D utilities.
In addition, repeated measures linear models were used
to predict mean OAB-5D and EQ-5D utilities according
to severity levels of the 2 symptoms, with study identifier
and several clinical and socio-demographic covariables.
The listed covariates were removed from the models
if not significant at 5%: gender, age, race, body mass
index (BMI), type OAB (urgency incontinence, frequency
or mixed), prior OAB surgery, previous OAB drug and
duration of OAB symptoms.
Tobit and beta regression models were also estimated
with repeated measurements random effect and the same
covariates as above mentionned. Minimizing the Root
Mean Squared Error (RMSE) was used as criterion to
define the best model.
The purpose of this model was to provide a way to
derive utilities from the micturition diary data, which
are usually collected in trials of OAB treatments.
Finally, as a test of sensitivity of the instruments,
utility changes from baseline to week 12 were esti-
mated according to response in symptoms, defined as
3 possible items: “improvement higher than 1 level of
symptoms”, “stable” or “worsening higher than 1 level
of symptoms”. Linear models with covariables gender,
age, study and response as fixed effects, and geograph-
ical region as random effect were estimated to provide
adjusted means (SD) of utility changes from baseline
to week 12 by response level. Models were run for overall
population, patients with mild symptoms at baseline (level
1 to 3 in micturitions frequency for response in micturi-
tions frequency, or level 1 to 3 in incontinence episodes
for response in incontinence) and patients with severe
symptoms at baseline (level 4 or 5 in micturitions fre-
quency, or in incontinence episodes).Results
Patient characteristics in pooled clinical trials
Across the three studies, the total number of patients
was 4427, of which 3179 were female (71.8%). The
majority of patients were from Europe (SCORPIO and
CAPRICORN trials) with 1392 from Western Europe
and 1095 from Eastern Europe (31.4% and 24.7% re-
spectively). The remainders of the patients were from
USA and Canada (ARIES and CAPRICORN trials) (39.0%
and 4.8% respectively). Patients’ mean age was 59.4
(±12.9) years, 52.0% were previously treated with anti-
muscarinics. The baseline mean daily numbers of
micturitions were 11.6 (±2.9), 11.7 (±3.4), 11.6 (±3.1)
and 11.6 (±3.1) respectively for SCORPIO, ARIES,
CAPRICORN and pooled trials (Table 1). The baseline
mean daily numbers of incontinence episodes were 1.7
(±2.4), 2.1 (±2.7), 2.3 (±2.3) and 1.8 (±2.5) respectively
Table 1 Baseline demographic and clinical characteristics
Patient characteristicsa N (%) or mean (±SD)b
SCORPIO (n = 1906) ARIES (n = 1270) CAPRICORN (n = 1251) Pooled trials (n = 4427)
Age 59.1 (±12.4) 60.2 (±13.4) 59.1 (±13.0) 59.4 (±12.9)
Female 1372 (72.0%) 950 (74.8%) 857 (68.5%) 3179 (71.8%)
BMI 27.8 (±4.9) 30.2 (±7.0) 29.4 (±6.4) 28.9 (±6.1)
Geographical region
Western Europe 1906 (54.2%) 0 (0.0%) 359 (28.7%) 1392 (31.4%)
Eastern Europe 873 (45.8%) 0 (0.0%) 222 (17.8%) 1095 (24.7%)
USA 0 (0.0%) 127 (10.0%) 584 (46.7%) 1727 (39.0%)
Canada 0 (0.0%) 1143 (90.0%) 86 (6.9%) 213 (4.8%)
Previously treated with antimuscarinics 946 (49.6%) 714 (56.2%) 642 (51.3%) 2302 (52.0%)
Baseline mean number of micturitions per 24 h 11.6 (±2.9) 11.7 (±3.4) 11.6 (±3.1) 11.6 (±3.1)
Baseline mean number of incontinence episodes per 24 h 1.7 (±2.4) 2.1 (±2.7) 2.3 (±2.3) 1.8 (±2.5)
aBMI: Body mass index; USA: United States of America.
bSD: Standard deviation.
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(Table 1).
Description of utilities according to symptoms severity
Mean utilities were 0.82 (±0.21) for EQ-5D and 0.86
(±0.09) for OAB-5D, for all patients and visits combined,
with values ranging from−0.59 to 1 for EQ-5D, and from
0.61 to 1 for OAB-5D. A moderate correlation between
OAB-5D and EQ-5D was found (r = 0.34, p < 0.0001).
Mean EQ-5D and OAB-5D utilities steadily decreased
with increasing symptom severity. OAB-5D provided higher
values than EQ-5D, whereas SD estimates were lower for
OAB-5D (Table 2). Ranges of utilities from the most severe
symptom level to the least were slightly larger for OAB-5D









Micturitions/24 h 1 < 8 21.2 0.8
2 8 - < =10 30.7 0.8
3 10 - < =12 22.7 0.8
4 12 - < = 14 13.2 0.8
5 > 14 12.3 0.7
Incontinence episodes/24 h 1 0 50.3 0.8
2 > 0 - < = 1 19.7 0.8
3 1 - < =2 11.0 0.8
4 2 - < =3 6.9 0.7
5 > 3 12.2 0.7
aSD: Standard deviation.
bt-test to test the null hypothesis that the adjusted difference equals zero.and 0.09 for micturitions and incontinence levels, respect-
ively for EQ-5D).
Adjusted estimates of utility by symptom frequency level
are presented in Figure 1. For severe levels of micturition
frequency (4 and 5), difference in utilities between the two
instruments was not statistically significant. However, in
the lower levels of severity (1 and 2), utilities generated by
OAB-5D were higher and differences with EQ-5D were
statistically significant (p < 0.0001) (Table 2).
Similar trends were observed for incontinence (Figure 1B).
Utility values were not significantly different between
EQ-5D and OAB-5D for the most severe levels of incon-
tinence (3, 4 and 5). Differences in utilities between the
two instruments became highly significant in less severe









5 (±0.21) 0.90 (±0.08) 0.046 (±0.396) <.0001
4 (±0.20) 0.87 (±0.09) 0.025 (±0.458) <.0001
2 (±0.21) 0.85 (±0.09) 0.015 (±0.401) 0.0205
0 (±0.22) 0.82 (±0.09) 0.007 (±0.325) 0.3073
8 (±0.23) 0.80 (±0.09) 0.007 (±0.331) 0.3477
5 (±0.19) 0.89 (±0.08) 0.032 (±0.470) <.0001
2 (±0.20) 0.85 (±0.09) 0.019 (±0.320) 0.0006
0 (±0.22) 0.83 (±0.09) 0.009 (±0.262) 0.1529
8 (±0.23) 0.81 (±0.09) 0.006 (±0.229) 0.4157
































Figure 1 Adjusted utility estimates of EQ-5D and OAB-5D according to symptom frequency level. A–Adjusted utility estimates of EQ-5D
and OAB-5D according to micturition frequency level; B–Adjusted utility estimates of EQ-5D and OAB-5D according to incontinence episode
frequency level.
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symptom levels
Age, gender, BMI, previous OAB treatment (yes/no) and
study identifier were selected as adjustment variables in
the regression models.
For EQ-5D utility modeling, the estimated RMSE for
the linear model, the Beta model and the Tobit model
were respectively 0.20829, 0.23819 and 0.26237. For
OAB-5D utility modeling, the resulting RMSE for the
linear model, the Beta model and the Tobit model were
respectively 0.08000, 0.09245 and 0.09085. The linear
model was consequently selected as the best model for
both utility scores.
The estimated regression coefficients confirmed that
utilities decreased with symptom severity after adjusting
for patient characteristics (Table 3). Micturitions and in-
continence appeared to have similar impact on EQ-5D,
but micturitions had greater impact on OAB-5D utilities
than incontinence. Improvement of incontinence level
from 5 to 1 (i.e. from >3 incontinence episodes per day
to 0) was associated with an increase of 0.052 in EQ-5D
utility (p < 0.0001) and 0.076 in OAB-5D utility (p < 0.0001),
at equal micturitions symptoms. Similarly, improvementof micturitions frequency from level 5 to 1 (i.e. from >7
episodes per day to to ≤1) was associated with an in-
crease of 0.056 in EQ-5D utility (p < .0001) and 0.088
in OAB-5D utility (p < 0.0001), at equal incontinence
symptoms.
Utility values were estimated by the model for the least
severe OAB state (level 1 for both symptoms) and the
most severe (level 5 for both symptoms) OAB state and
for average age (59.4 years), average BMI (28.9 kg/m2),
gender (71.8% female), previous OAB treatment (52.0%)
and study (43.1% SCORPIO, 28.7% ARIES, 28.3%
CAPRICORN). These were respectively 0.870 and 0.762
based on EQ-5D (a difference of 0.108) and 0.923 and
0.759 based on OAB-5D (difference of 0.164).
The proportions of variance explained by the models
(R2) were 26.1% for OAB-5D and 5.1% for EQ-5D.
Responsiveness of HRQoL and clinical symptoms
More than half of the patients (56.4%) reported an im-
provement of at least 1 level in micturitions while 31.1%
of them remained stable (all treatment arms combined).
For incontinence episodes, patients who experienced im-
provement and those who remained stable represented
Table 3 Equations to predict EQ-5D and OAB-5D utilities from symptom frequency level
Effect EQ-5D utility OAB-5D utility
β estimate β SEa P valueb β estimate β SEa P valueb
Intercept 0.940 0.0230 <.0001 0.766 0.0085 <.0001
Age −0.001 0.0002 0.0006 0.0003 0.0001 <.0001
Gender: female vs. male −0.021 0.0063 0.0006 0.005 0.0024 0.0551
BMI −0.003 0.0004 <.0001 −0.001 0.0002 0.0003
Previously treated with antimuscarinics −0.019 0.0055 0.0006 −0.017 0.0021 <.0001
Micturitions level: 1 vs. 5 0.056 0.0057 <.0001 0.088 0.0022 <.0001
Micturitions level: 2 vs. 5 0.040 0.0052 <.0001 0.055 0.0021 <.0001
Micturitions level: 3 vs. 5 0.029 0.0051 <.0001 0.035 0.0020 <.0001
Micturitions level: 4 vs. 5 0.019 0.0051 0.0002 0.019 0.0020 <.0001
Incontinence episodes level: 1 vs. 5 0.052 0.0052 <.0001 0.076 0.0020 <.0001
Incontinence episodes level: 2 vs. 5 0.037 0.0052 <.0001 0.048 0.0020 <.0001
Incontinence episodes level: 3 vs. 5 0.022 0.0054 <.0001 0.025 0.0021 <.0001
Incontinence episodes level: 4 vs. 5 0.011 0.0058 0.0481 0.012 0.0023 <.0001
Study: SCORPIO vs. CAPRICORN −0.019 0.0081 0.0174 −0.012 0.0030 <.0001
Study: ARIES vs. CAPRICORN −0.008 0.0083 0.3409 0.004 0.0031 0.1984
aSE: Standard error.
bt-test to test the null hypothesis that the associated β estimate equals zero.
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tom worsening occurred in respectively 12.5% and 8.1%
of patients for micturitions and incontinence episodes
(Table 4A).
In the overall population, mean changes from baseline
in utility were positive in all groups of patients, those with
improving, stable or worsening symptoms, and were
greater in responders than in non-responders. There were
no significant differences in change from baseline utility
between worsening response and stable response for
EQ-5D (p-values of 0.7291 and 0.0662 for micturi-
tions and incontinence episodes respectively). However,
differences became significant when using OAB-5D
(p-value < 0.0001 for each symptom) (Table 4A).
In patients with mild micturition frequency (levels 1 to 3),
the change from baseline in EQ-5D utility did not
significantly differ between improvement and stable
response (p-value of 0.3518) (Table 4B). When using
OAB-5D, differences in utility were significant between
improvement and stable response (p-value < 0.0001) as
well as between worsening response and stable response)
(p-value < 0.0001).
In severe cases, changes in micturition frequency
and incontinence episodes were significantly associated
with changes in EQ-5D utility. Thus, differences were
significant between improvement and stable response
(p = 0.0004 for both symptoms). Similar results were
observed for OAB-5D (p < .0001 for both symptoms). Nosignificant differences were observed between worsen-
ing response and stable response for both EQ-5D and
OAB-5D (p-values of 0.3865 and 0.7158 for micturitions
and incontinence episodes, respectively) (Table 4C).
Overall changes in utility from baseline values were
greater with OAB-5D for all symptoms, in both improv-
ing and stable patients. In addition, differences in utility
changes between improving and stable patients were
higher with OAB-5D for each symptom (+0.037 with
OAB-5D and +0.019 with EQ-5D for micturitions; +0.039
and +0.025 for incontinence) (Table 4A).
Discussion
This study demonstrated that both utilities derived from
EQ-5D and OAB-5D increased as OAB symptoms
improved. Utilities were similar between the two in-
struments for severe levels of symptoms, but OAB-5D
utilities were greater than EQ-5D utilities for lower levels
of severity. Thus, the OAB-5D had a greater range of
variation according to symptom severity. It is not sur-
prising that, on average, EQ-5D utilities are lower than
OAB-5D utilities since the generic instrument EQ-5D
captures effects of patients’ co-morbidities on HRQL.
The fact that incremental utilities between symptom levels
are different between EQ-5D and OAB-5D is more note-
worthy, considering that both instruments are expected to
provide values on the same scale (where 1 represents
perfect health and 0 a health state equivalent to death),
Table 4 Responsiveness of HRQoL and clinical symptoms
A. Overall population
Clinical symptom Response in symptoms N (%) Change from baseline in utility EQ-5D,
adjusted mean (±SD)a
P value vs. ‘Stable’b Change from baseline in utility OAB-5D,
adjusted mean (±SD)a
P value vs. ‘Stable’b
Micturitions/24 h Improvement ≥ 1 level 2286 (56.4%) 0.046 (±0.213) 0.0058 0.076 (±0.092) <.0001
Stable 1260 (31.1%) 0.027 (±0.202) NA 0.039 (±0.087) NA
Worsening ≥ 1 level 506 (12.5%) 0.023 (±0.195) 0.7291 0.021 (±0.085) 0.0001
Incontinence episodes/24 h Improvement ≥ 1 level 1874 (46.3%) 0.053 (±0.223) 0.0002 0.081 (±0.096) <.0001
Stable 1849 (45.6%) 0.028 (±0.206) NA 0.042 (±0.089) NA
Worsening ≥ 1 level 329 (8.1%) 0.007 (±0.197) 0.0662 0.022 (±0.086) <.0001
B. Patients with mild symptoms at baseline (level 1 to 3 in terms of micturitions frequency, or incontinence episodes)
Clinical symptom Response in symptoms N (%) Change from baseline in utility EQ-5D,
adjusted mean (±SD)a
P value vs. ‘Stable’b Change from baseline in utility OAB-5D,
adjusted mean (±SD)a
P value vs. ‘Stable’b
Micturitions/24 h Improvement ≥ 1 level 1329 (50.7%) 0.046 (±0.205) 0.3518 0.079 (±0.089) <.0001
Stable 863 (32.9%) 0.038 (±0.197) NA 0.047 (±0.085) NA
Worsening ≥ 1 level 432 (16.5%) 0.029 (±0.189) 0.3886 0.021 (±0.082) <.0001
Incontinence episodes/24 h Improvement ≥ 1 level 1038 (35.9%) 0.049 (±0.197) 0.0416 0.079 (±0.099) <.0001
Stable 1564 (54.1%) 0.033 (±0.191) NA 0.046 (±0.102) NA
Worsening ≥ 1 level 287 (9.9%) 0.010 (±0.188) 0.0628 0.023 (±0.087) <.0001
C. Patients with severe symptoms at baseline (level 4 or 5 in terms of micturitions frequency, or incontinence episodes)
Clinical symptom Response in symptoms N (%) Change from baseline in utility EQ-5D,
adjusted mean (±SD)a
P value vs. ‘Stable’b Change from baseline in utility OAB-5D,
adjusted mean (±SD)a
P value vs. ‘Stable’b
Micturitions/24 h Improvement ≥ 1 level 957 (67.0%) 0.046 (±0.250) 0.0004 0.074 (±0.098) <.0001
Stable 397 (27.8%) 0.002 (±0.219) NA 0.020 (±0.090) NA
Worsening ≥ 1 level 74 (5.2%) −0.009 (±0.208) 0.6873 0.022 (±0.090) 0.8938
Incontinence episodes/24 h Improvement ≥ 1 level 836 (71.9%) 0.064 (±0.299) 0.0004 0.078 (±0.143) <.0001
Stable 285 (24.5%) 0.012 (±0.246) NA 0.014 (±0.111) NA
Worsening ≥ 1 level 42 (3.6%) −0.019 (±0.219) 0.3865 0.008 (±0.094) 0.7158
A. aSD: Standard deviation. bt-test to test the null hypothesis that the associated utility change equals the utility change in patients with “Stable” response. NA: Not applicable.
B. aSD: Standard deviation. bt-test to test the null hypothesis that the associated utility change equals the utility change in patients with “Stable” response. NA: Not applicable.
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The correlation between OAB-5D and EQ-5D in general
population was moderate (r = 0.34; p < 0.0001). This is
likely attributable to the noise around EQ-5D utilities,
corroborated by the larger standard deviation around
EQ-5D utilities, which may reflect natural variations in
health status not related to OAB.
UK population norms for EQ-5D from a nationally
representative interview survey of 3395 men and women
aged 18 or over living in the UK were 0.81 (±0.26) for
females and 0.78 (±0.28) for males aged from 55 to
64 years [20]. In the US, population norms for EQ-5D
were 0.84 (SE of 0.01) for females and 0.86 (SE of 0.01)
for males, in the same age group, 55 to 64 years [21]. In
the studied population, the mean EQ-5D utility, based
on UK TTO tariff, was 0.84 (±0.21). It is thus slightly
higher than general population.
In a cost-effectiveness model evaluating tolterodine
compared to no treatment in Sweden, Kobelt et al. [22]
used a Markov model with five health states according
to the number of micturitions and leakages per day,
where state 1 was considered “mild” and state 5 “severe”.
They obtained utility weights for the states by a linear
regression analysis of the correlation between urinary
symptoms and EQ-5D scores in a Swedish willingness-
to-pay survey [7]. The following utility values were
reported for different health states: level 1 (M + L <9):
0.742, level 2: (M+ L < 12): 0.712, level 3 (12 ≤M+L< 15):
0.676, level 4 (15 ≤M+ L < 18): 0.640 and level 5 (M +
L ≥ 18): 0.598. Thus the difference between the least
and more severe states was 0.144. Similarly, in this study,
a model was provided to predict EQ-5D utilities for differ-
ent health states, defined according to frequency of mic-
turitions and incontinence episodes. EQ-5D utilities were
higher, overall, ranging from 0.762 for the most severe
state to 0.870 for the least severe states, but the differ-
ence in utilities of 0.108 between the two extreme OAB
states was comparable to that reported by Kobelt et al.
In addition, an equation was provided to generate
utilities for OAB states based on OAB-5D, with adjust-
ment on age and gender. The two equations, based on
EQ-5D and OAB-5D, can be used to derive utilities from
clinical trials for which no utility instrument is provided.
It should be noted that the predictive power of the EQ-5D
equation is very low, whereas it appears acceptable for
OAB-5D. This implies that a very large number of patients
would be required to detect a difference in utility between
different groups of patients using the EQ-5D equation.
Another limitation of those regression models is that
they do not capture potential effects of non-urological
dimensions. Measuring the impact of adverse events on
utilities using trial data was difficult since the periods
during which patients experienced adverse events rarely
coincided with dates of assessment visits. Furthermore,the OAB-5D system has no dimension related to the im-
pact of adverse events of OAB treatments on HRQoL,
whereas the EQ-5D, as a generic instrument, is expected
to capture deteriotations in HRQoL related to adverse
events.
An important finding based on the regression ana-
lyses performed in this study is that micturition fre-
quency does affect the utility scores, even when adjusting
on incontinence episodes. The interaction between mic-
turition frequency and incontinence episodes was found
not to be significant within the utility linear regression
models (p = 0.1283), meaning that the numbers of
micturition frequency and incontinence episodes have
effects on utilities independently of each other. The ef-
fects of different symptoms were then assumed to be
additive.
Both instruments were able to differentiate improving
patients from stable patients. However the change in
EQ-5D utility did not differ significantly between pa-
tients with improving or stable micturitions symptoms,
among those with mild micturition frequency at baseline.
Moreover, EQ-5D did not detect any significant difference
between patients with stable symptoms and those with
worsening symptoms in overall population. These find-
ings highlight the greater responsiveness of OAB-5D as
compared to EQ-5D, especially for patients with mild
OAB. Additionnaly, this analysis revealed that utilities
improved in stable patients and even in patients with
worsening symptoms, among those with mild symptoms
at baseline. Possible explanations for this unexpected
trend would be that patients felt quite unwell at the time
of entering the trial, and might have learned to better cope
with their condition over time.Conclusions
In conclusion, this study showed that both EQ-5D and
OAB-5D can detect changes in severity of OAB, especially
in severe cases. Estimated differences in utilities between
different OAB states are greater with OAB-5D, thus the
choice of the instrument matters. Using EQ-5D to meas-
ure utilities has the advantage to generate values that can
be compared to other conditions, and it can capture
the impact of adverse events. However, large samples
of patients are required to detect differences between
different treatments or patient groups. EQ-5D may not
be as sensitive as OAB-5D in measuring differences be-
tween treatments in milder cases of OAB. Contrary to
EQ-5D, OAB-5D detects the difference between patients
with worsening and stable symptoms. OAB-5D and EQ-5D
can both be useful to derive utilities from clinical trial
data and perform cost-effectiveness analyses in OAB,
although they will lead to different incremental cost-
effectiveness ratios.
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